Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 152
Filter
1.
Am J Med Genet ; 96(1): 56-60, 2000 Feb 07.
Article in English | MEDLINE | ID: mdl-10686553

ABSTRACT

There is evidence indicating that density of 5-HT2A receptors is altered in brain regions of depressed suicide victims and in platelets of suicidal subjects with major depression or schizophrenia. Recent studies have also shown an association between the allele C of 102T/C polymorphism in the 5-HT2A receptor gene and schizophrenia. The present investigation tested the hypothesis that the observed changes in 5-HT2A receptor density in platelets of patients with major depression are a trait rather than state phenomenon and are associated with the 102 C allele in 5-HT2A receptor gene in a sample of 120 patients with major depression and a group of 131 control subjects comparable with respect to age, sex, and ethnic background. The allele and genotype frequencies of 102T/C polymorphism in 5-HT2A receptor gene were compared between patients and control subjects and between suicidal and non-suicidal patient groups. The major finding of this study was a significant association between the 102 C allele in 5-HT2A receptor gene and major depression, chi(2) = 4.5, df = 1, P = 0.03, particularly in patients with suicidal ideation, chi(2) = 8.5, df = 1, P < 0.005. Furthermore, we found that patients with a 102 C/C genotype had a significantly higher mean HAMD item 3 score (indication of suicidal ideation) than T/C or T/T genotype patients. Our results suggest that the 102T/C polymorphism in 5-HT2A receptor gene is primarily associated with suicidal ideation in patients with major depression. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 96:56-60, 2000.


Subject(s)
Depressive Disorder, Major/genetics , Polymorphism, Genetic , Receptors, Serotonin/genetics , Suicide, Attempted/psychology , Adult , Base Sequence , DNA Primers , Depressive Disorder, Major/psychology , Female , Genotype , Humans , Male , Receptor, Serotonin, 5-HT2A
2.
Can J Psychiatry ; 44(9): 887-92, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10584158

ABSTRACT

OBJECTIVE: To determine if the inclusion of a placebo control in clinical trials of schizophrenia affects retention rates in the first 35 days of inclusion relative to trials that did not have a placebo control. METHOD: This was a retrospective study of 8 double-blind clinical trials, 5 of which had a placebo control while 3 did not. Using survival analysis, retention rates between the placebo-controlled trials (PCTs) and the nonplacebo-controlled trials (NPCTs) were compared. Screening and percentage improvement on Brief Psychiatric Rating Scale and Positive and Negative Syndrome Scale scores were compared. RESULTS: Significantly more patients were retained in the 35-day period for NPCTs. Also, the PCT group had significantly more psychopathology at screening than did the NPCT group. CONCLUSIONS: Differences in retention rates between PCTs and NPCTs cannot be uniquely attributed to placebo itself.


Subject(s)
Antipsychotic Agents/pharmacology , Antipsychotic Agents/therapeutic use , Pirenzepine/analogs & derivatives , Remoxipride/pharmacology , Remoxipride/therapeutic use , Retention, Psychology/drug effects , Risperidone/pharmacology , Risperidone/therapeutic use , Schizophrenia/drug therapy , Adult , Benzodiazepines , Brief Psychiatric Rating Scale , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Male , Olanzapine , Pirenzepine/pharmacology , Pirenzepine/therapeutic use , Retrospective Studies , Schizophrenia/diagnosis , Time Factors
3.
Can J Psychiatry ; 44(8): 805-7, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10566112

ABSTRACT

OBJECTIVE: To examine whether, like pure obsessive-compulsive disorder, obsessive-compulsive spectrum disorders are treatable with a selective serotonin reuptake inhibitor (SSRI). METHOD: Case histories of patients prescribed paroxetine for compulsive collecting, skin-picking, and trichotillomania were reviewed. RESULTS: All patients were successfully treated with paroxetine. CONCLUSIONS: Obsessive-compulsive spectrum disorders may share a serotonin-related dysfunction, and SSRIs may prove effective in their treatment.


Subject(s)
Obsessive-Compulsive Disorder/drug therapy , Paroxetine/therapeutic use , Selective Serotonin Reuptake Inhibitors/therapeutic use , Adult , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Obsessive-Compulsive Disorder/diagnosis , Obsessive-Compulsive Disorder/psychology , Paroxetine/adverse effects , Selective Serotonin Reuptake Inhibitors/adverse effects , Treatment Outcome , Trichotillomania/diagnosis , Trichotillomania/drug therapy , Trichotillomania/psychology
4.
Psychiatry Res ; 87(1): 1-5, 1999 Jul 30.
Article in English | MEDLINE | ID: mdl-10512149

ABSTRACT

The monoamine neurotransmitters serotonin, norepinephrine and dopamine have been implicated in the pathogenesis of depression, schizophrenia and mood disorders. The mechanism of action of certain antidepressant drugs, particularly the tricyclics and the newly available norepinephrine and serotonin reuptake inhibitors (NSRIs) drugs, venlafaxine and nefazodone, suggest that the norepinephrine transporter, which is a target for these antidepressant drugs, and its malfunction may be involved in major depression. In this association study, we tested the hypothesis that variants of the human norepinephrine transporter (NET) gene confer susceptibility to major depression. One hundred and five patients with major depression and 74 unrelated matched controls were analyzed for a silent 1287G/A polymorphism (NET-8) in exon 9 of the NET gene. No significant differences in genotype or allele frequencies were found between controls and patients, nor between subgroups of depressed patients classified by suicidal ideation. In addition, 60 controls and 60 patients were genotyped for a missense substitution Thr99Ile in exon 2 of the NET gene (NET-1), but only one control was heterozygous for this variant. These results suggest that the NET gene is unlikely to be involved in the susceptibility to major depression.


Subject(s)
Carrier Proteins/genetics , Depressive Disorder/genetics , Genetic Predisposition to Disease/genetics , Polymorphism, Genetic/physiology , Symporters , Adult , Alleles , Case-Control Studies , Chi-Square Distribution , Female , Genotype , Humans , Male , Mutation, Missense , Norepinephrine Plasma Membrane Transport Proteins , Polymerase Chain Reaction , Suicide/psychology
5.
Biol Psychiatry ; 46(2): 196-201, 1999 Jul 15.
Article in English | MEDLINE | ID: mdl-10418694

ABSTRACT

BACKGROUND: There is evidence indicating that serotonin uptake and density of 5-HT2A receptors are altered in brain regions of depressed suicide victims and in platelets of depressed suicidal subjects. The present investigation tested the hypothesis that these changes in the serotonergic system in depressed suicide victims are trait rather than state markers and associated with a polymorphism in respective candidate genes. METHODS: Two polymorphic variants (102T/C polymorphism and His452Tyr functional polymorphism) of the 5-HT2A receptor gene and a functional polymorphism in the 5' regulatory region of the 5-HT transporter gene, have been determined in genomic DNA obtained from postmortem brain samples of 24 depressed suicide victims and 31 control subjects of the same ethnic background. In a subset of subjects, density (Bmax) of 5-HT uptake sites (labeled with 3H-paroxetine) and of 5-HT2A receptors (labeled with 3H-ketanserin) was also determined in prefrontal cortex samples. RESULTS: The major finding of this study was a significantly higher frequency of the 5-HT transporter gene long (L) allele (chi 2 = 3.9, df = 1; p = .048) in depressed suicides. No significant differences between suicides and controls were observed for the 102T/C polymorphism and His452Tyr polymorphism of 5-HT2A receptor gene. The density of 3H-paroxetine binding sites tended to be higher in subjects expressing the short (S) allele of 5-HT transporter gene. Furthermore, there was a significant difference in serotonin transporter binding sites between the genotype S/S and combined genotypes S/L and L/L. CONCLUSIONS: Our finding provides the first evidence suggesting that a functional polymorphism in the regulatory region of serotonin transporter gene may be associated with suicide in depressed subjects.


Subject(s)
Alleles , Carrier Proteins/genetics , Depressive Disorder/genetics , Gene Expression/genetics , Gene Frequency/genetics , Serotonin/genetics , Suicide/psychology , Adult , Aged , Binding Sites , Biological Transport/genetics , Cell Count , Culture Techniques , DNA/analysis , Depressive Disorder/psychology , Female , Genetic Variation/genetics , Humans , Male , Middle Aged , Polymorphism, Genetic/genetics , Prefrontal Cortex/cytology , Prefrontal Cortex/metabolism , Serotonin/metabolism
6.
Int Clin Psychopharmacol ; 14(2): 101-12, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10220125

ABSTRACT

The primary objective of this study was to evaluate the efficacy, safety and tolerability of remoxipride (controlled release) versus haloperidol in patients with negative symptoms. The study comprised a multicentre, randomised, double-blind, parallel-group clinical trial. Two hundred and five patients were randomised to either remoxipride or haloperidol. Patients eligible for this study were aged 18-65 years, met the DSM-III-R diagnosis for chronic schizophrenia and the Positive and Negative Symptoms Scale (PANSS) criteria for predominant negative symptoms. There was a statistically significant reduction in the PANSS scores of at least 20% from baseline to last rating for 39 remoxipride (49.4%) and 45 haloperidol (47.6%) treated patients. There were no statistical differences found between the two treatment groups with respect to improvement of negative symptoms and adverse events. The PANSS data suggest that both remoxipride and haloperidol improve the cluster of negative symptoms concerned with social functioning. In addition, the design of the study provides a methodology that is appropriate to the study of primary negative symptoms in schizophrenia.


Subject(s)
Haloperidol/therapeutic use , Remoxipride/therapeutic use , Schizophrenia/drug therapy , Schizophrenic Psychology , Adult , Delayed-Action Preparations/adverse effects , Delayed-Action Preparations/therapeutic use , Double-Blind Method , Female , Haloperidol/adverse effects , Humans , Male , Psychiatric Status Rating Scales , Remoxipride/adverse effects
7.
J Clin Psychopharmacol ; 18(4): 268-73, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9690691

ABSTRACT

Ipsapirone, an azapirone with 5-hydroxytryptamine (5-HT1A) partial agonist activity, has been shown in preliminary studies to be effective in the treatment of major depressive disorder. This 8-week, randomized, double-blind study compared the efficacy, safety, and tolerability of three fixed doses of controlled-release ipsapirone (10-, 30-, and 50-mg dose once daily) with placebo in 410 patients with moderate to severe major depression (Hamilton Rating Scale for Depression [HAM-D] score > or = 20). The 10-mg ipsapirone treatment arm was discontinued early in the study. A total of 390 patients were eligible for evaluation in the intent-to-treat sample. The primary efficacy variable was the change in HAM-D total score from baseline to visit 8. There was no significant difference in efficacy in the two treatment groups versus the placebo group. The overall treatment response, defined as a 50% decrease in the HAM-D total score from baseline, was 43% with ipsapirone 50 mg given once daily, 34% with ipsapirone 30 mg given once daily, and 35% with placebo. In subanalyses, ipsapirone 50 mg given once daily was superior to placebo according to the HAM-D Core Depression (mood, guilt, interest, psychomotor activity) subtotal (p = 0.0453) and Melancholic item (p = 0.0225). Ipsapirone 30 mg given once daily was superior to placebo only in patients with moderate depression (baseline HAM-D total score < or = 25; p = 0.0100). The most common adverse effect in all groups was headache. The only dose-dependent adverse effects were dizziness and nausea.


Subject(s)
Depressive Disorder, Major/drug therapy , Pyrimidines/administration & dosage , Serotonin Receptor Agonists/administration & dosage , Adolescent , Adult , Aged , Ambulatory Care , Canada , Delayed-Action Preparations , Depressive Disorder, Major/diagnosis , Depressive Disorder, Major/psychology , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Personality Inventory , Pyrimidines/adverse effects , Serotonin Receptor Agonists/adverse effects , Treatment Outcome
8.
J Psychiatry Neurosci ; 23(1): 9-11, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9505056
9.
Eur Neuropsychopharmacol ; 8(1): 55-66, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9452941

ABSTRACT

These guidelines for depot antipsychotic treatment in schizophrenia were developed during a two-day consensus conference held on July 29 and 30, 1995 in Siena, Italy. Depot antipsychotic medications were developed in the 1960s as an attempt to improve the long-term treatment of schizophrenia (and potentially other disorders benefiting from long-term antipsychotic medication). Depot drugs as distinguishable from shorter acting intramuscularly administered agents can provide a therapeutic concentration of at least a seven day duration in one parenteral dose. The prevention of relapse in schizophrenia remains an enormous public health challenge worldwide and improvements in this area can have tremendous impact on morbidity, mortality and quality of life, as well as direct and indirect health care costs. Though there has been debate as to what extent depot (long-acting injectable) antipsychotics are associated with significantly fewer relapses and rehospitalizations, in our view when all of the data from individual trials and metaanalyses are taken together, the findings are extremely compelling in favor of depot drugs. However in many countries throughout the world fewer than 20% of individuals with schizophrenia receive these medications. The major advantage of depot antipsychotics over oral medication is facilitation of compliance in medication taking. Non-compliance is very common among patients with schizophrenia and is a frequent cause of relapse. In terms of adverse effects, there are not convincing data that depot drugs are associated with a significantly higher incidence of adverse effects than oral drugs. Therefore in our opinion any patient for whom long-term antipsychotic treatment is indicated should be considered for depot drugs. In choosing which drug the clinician should consider previous experience, personal patient preference, patients history of response (both therapeutic and adverse effects) and pharmacokinetic properties. In conclusion the use of depot antipsychotics has important advantages in facilitating relapse prevention. Certainly pharmacotherapy must be combined with other treatment modalities as needed, but the consistent administration of the former is often what enables the latter.


Subject(s)
Antipsychotic Agents/therapeutic use , Schizophrenia/drug therapy , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/adverse effects , Humans , Schizophrenic Psychology , Secondary Prevention
12.
J Psychiatry Neurosci ; 22(4): 244-8, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9262046

ABSTRACT

In a large, multicenter, double-blind study of the effect of haloperidol and the atypical antipsychotic remoxipride on improvement of negative symptoms in schizophrenia, quality of life was also assessed using a modified version of the Sickness Impact Profile (SIP). Compared with previous studies, this study had a longer duration (28 weeks), and the dose of the comparator, haloperidol, was much lower. At the end of the study, compared with the baseline, both treatment groups reported comparable improvement in negative symptoms as defined by the protocol (at least 20% improvement). Similarly, both groups showed comparable changes on global and multidimensional self-assessments of quality of life. All the subfactors of the modified version of the SIP were similar in both groups, except for the subfactor that relates to alertness behavior, which possibly reflects remoxipride's lack of any sedating properties compared with haloperidol. This study presents an approach for inclusion of quality of life as an outcome measure in the design of clinical trials of new antipsychotic medications.


Subject(s)
Antipsychotic Agents/adverse effects , Antipsychotic Agents/therapeutic use , Haloperidol/adverse effects , Quality of Life , Remoxipride/adverse effects , Schizophrenia/drug therapy , Adolescent , Adult , Aged , Double-Blind Method , Female , Humans , Male , Middle Aged
13.
J Psychiatry Neurosci ; 22(2): 118-26, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9074306

ABSTRACT

The objective of the present study was to compare the safety and efficacy of moclobemide versus fluoxetine in adult patients with major depressive disorder. The design of the study was a multicenter, double-blind, comparative, and randomized trial. A 1- to 2-week single-blind placebo washout phase was followed by 6 weeks of double-blind treatment with moclobemide or fluoxetine. A total of 150 patients were enrolled in the study. There were 128 patients eligible to be randomized, with 66 patients receiving moclobemide and 62 patients receiving fluoxetine. At the termination of the study, patients in the moclobemide group were receiving a mean dose of 440 mg +/- 123 mg, while the mean dose in the fluoxetine group was 35 mg +/- 8 mg. No significant treatment differences were found for any of the efficacy parameters. Headache and nausea were the most frequently reported adverse events in both treatment groups. Headache and blurred vision were reported significantly more often (P < 0.05) in the fluoxetine group, whereas significantly more dry mouth was reported (P < 0.05) in the moclobemide group. These results provide supporting evidence of the comparable efficacy of moclobemide and fluoxetine and the better tolerability of moclobemide when used in the treatment of major depressive disorder.


Subject(s)
Antidepressive Agents, Second-Generation/therapeutic use , Antidepressive Agents/therapeutic use , Benzamides/therapeutic use , Fluoxetine/therapeutic use , Adult , Antidepressive Agents/adverse effects , Antidepressive Agents, Second-Generation/adverse effects , Benzamides/adverse effects , Depressive Disorder/diagnosis , Depressive Disorder/drug therapy , Depressive Disorder/psychology , Double-Blind Method , Female , Fluoxetine/adverse effects , Humans , Male , Middle Aged , Moclobemide , Treatment Outcome
14.
Psychiatry Res ; 66(2-3): 73-85, 1997 Feb 07.
Article in English | MEDLINE | ID: mdl-9075272

ABSTRACT

This study examined, in the largest sample of major depressives reported so far, platelet serotonergic parameters (5-HT uptake, [3H]paroxetine binding and 5-HT2A receptors measured by [3H]LSD binding) in 60 antidepressant-free depressed patients and 40 age- and gender-matched control subjects before treatment, and in 45 major depression patients during treatment with antidepressants. We found that, at baseline, the density (Bmax) of 5-HT2A receptors was significantly higher (by 39%) in depressed patients than in controls. Suicidal patients had significantly higher Bmax values than controls or non-suicidal patients. The rate of serotonin uptake (Vmax), but not the uptake at a single concentration, was significantly higher in depressed patients, particularly in females. There was no significant difference between the Kd or Bmax of [3H]paroxetine binding in control and depressed subjects. Treatment with antidepressant drugs of different pharmacological profile had no significant effect on the density of 5-HT2A receptors, nor did the receptor number predict the response to treatment. The affinity of serotonin uptake site for 5-HT and [3H]paroxetine significantly decreased during treatment with antidepressants, particularly SSRIs. Suppression of 5-HT uptake correlated with decreases in Hamilton depression (HAMD) scores. Our data suggest that the increased density of platelet 5-HT2A receptors may be associated with untreated major depression in antidepressant-free depressed patients, in particular those with suicidal thoughts. The persistence after antidepressant treatment and clinical improvement would suggest that up-regulation of 5-HT2A receptors is a trait rather than state phenomenon. Correlation of 5-HT uptake suppression with decreases in HAMD scores suggests that serotonin uptake inhibition is a relevant factor in antidepressant drug effect and clinical improvement.


Subject(s)
Antidepressive Agents/therapeutic use , Blood Platelets/drug effects , Carrier Proteins/drug effects , Depressive Disorder/drug therapy , Receptors, Drug/drug effects , Receptors, Serotonin/drug effects , Serotonin/physiology , Adolescent , Adult , Aged , Amitriptyline/adverse effects , Amitriptyline/therapeutic use , Antidepressive Agents/adverse effects , Depressive Disorder/blood , Depressive Disorder/psychology , Doxepin/adverse effects , Doxepin/therapeutic use , Female , Fluvoxamine/adverse effects , Fluvoxamine/therapeutic use , Follow-Up Studies , Humans , Male , Middle Aged , Personality Inventory , Receptor, Serotonin, 5-HT2A , Trazodone/adverse effects , Trazodone/therapeutic use , Treatment Outcome
15.
J Affect Disord ; 39(3): 175-84, 1996 Jul 29.
Article in English | MEDLINE | ID: mdl-8856421

ABSTRACT

The purpose of this study was to examine the utility of quantitative electroencephalography (QEEG) in the prediction of response to imipramine in depressed patients. Forty patients with a diagnosis of unipolar depression were subjected to a placebo washout and were assessed at pre-drug, 3 h after their first dose of imipramine, and again 2 weeks into treatment. Following 4 weeks of open imipramine treatment, patients were separated into responder (R) and non-responder (NR) groups. Statistical analysis of the 29 patients who completed the study focused on group comparisons of power spectral estimates in four frequency bands from multi-channel recordings. Results showed that theta power differentiated R and NR groups prior to treatment, in response to an acute test dose, as well as after 2 weeks of active drug treatment. Results based on this exploratory study suggest that QEEG may be a useful early predictor of response to imipramine.


Subject(s)
Antidepressive Agents, Tricyclic/therapeutic use , Depressive Disorder/drug therapy , Electroencephalography/drug effects , Imipramine/therapeutic use , Adult , Analysis of Variance , Antidepressive Agents, Tricyclic/pharmacology , Depressive Disorder/physiopathology , Electroencephalography/methods , Female , Humans , Imipramine/pharmacology , Male , Middle Aged , Single-Blind Method , Treatment Outcome
16.
J Psychiatry Neurosci ; 20(4): 265-70, 1995 Jul.
Article in English | MEDLINE | ID: mdl-7647079

ABSTRACT

The objective of this study was to determine if the placebo treatment response varied in subgroups of depressed patients (single episode, recurrent, and double depression). Data from placebo-treated patients from seven placebo-controlled clinical trials were pooled and analyzed retrospectively. The placebo response rate was highest for females with a single episode of depression (66.7%) and lowest for females with recurrent depressive episodes (13.3%). Among patients experiencing their first episode, placebo responders had lower Hamilton Rating Scale for Depression (HAMD) total scores at baseline and lower ratings of pschomotor retardation than nonresponders. For patients having a recurrence of an episode, placebo responders had lower baseline ratings of somatic anxiety. The major finding was that patients suffering from their first depressive episode differed from patients with recurrent depressive episodes in the rate of placebo response, effect of gender, and the clinical symptoms that were associated with a positive placebo response.


Subject(s)
Depressive Disorder/drug therapy , Placebo Effect , Antidepressive Agents/therapeutic use , Clinical Trials as Topic , Depressive Disorder/diagnosis , Depressive Disorder/psychology , Female , Humans , Male , Personality Inventory , Recurrence , Retrospective Studies
18.
Int Clin Psychopharmacol ; 10(1): 51-4, 1995 Mar.
Article in English | MEDLINE | ID: mdl-7622805

ABSTRACT

A post-hoc analysis of nine controlled antidepressant trials examined the intensity of the initial anxiety and agitation of depressed patients improved by SSRIs compared with depressed patients improved by norepinephrine (NE) reuptake inhibitors, mixed NE/serotonin reuptake inhibitors and placebo. We report that SSRI responders were more anxious-agitated than NE reuptake inhibitor responders, suggesting a preferential efficacy of SSRIs in agitated depression.


Subject(s)
Anxiety Disorders/drug therapy , Depressive Disorder/drug therapy , Selective Serotonin Reuptake Inhibitors/therapeutic use , Adrenergic Uptake Inhibitors/therapeutic use , Adult , Aged , Anxiety Disorders/complications , Anxiety Disorders/psychology , Depressive Disorder/complications , Depressive Disorder/psychology , Double-Blind Method , Female , Humans , Male , Middle Aged , Norepinephrine/physiology , Psychiatric Status Rating Scales
19.
J Psychiatry Neurosci ; 20(1): 11-9, 1995 Jan.
Article in English | MEDLINE | ID: mdl-7865496

ABSTRACT

The uptake of [3H]5-HT and the density (Bmax) as well as affinity (Kd) of 5-HT uptake sites labelled with [3H]paroxetine and of 5-HT2 receptors labelled by [3H]LSD were determined in platelets from 25 medication-free patients with major depression and 20 normal controls. The density (Bmax) of 5-HT2 receptors was found to be significantly increased (by 52%) in platelets from depressed patients, particularly females. No changes were found in the affinity (Kd) of 5-HT2 receptors and in 5-HT uptake or [3H]paroxetine binding parameters. Density of 5-HT2 receptors positively correlated with that of [3H]paroxetine sites in control but not in depressed subjects. No correlation was found between the HAMD scores and Bmax of [3H]LSD binding. The results suggest that upregulation of platelet 5-HT2 receptors is a useful biological marker in major depression, particularly in females.


Subject(s)
Blood Platelets/metabolism , Depressive Disorder/blood , Receptors, Serotonin/physiology , Adolescent , Adult , Biomarkers/blood , Depressive Disorder/diagnosis , Depressive Disorder/psychology , Female , Humans , Lysergic Acid Diethylamide/pharmacokinetics , Male , Middle Aged , Paroxetine/pharmacokinetics , Radioligand Assay , Receptors, Serotonin/classification , Sex Factors , Up-Regulation/physiology
20.
Can J Psychiatry ; 39(9 Suppl 2): S59-64, 1994 Nov.
Article in English | MEDLINE | ID: mdl-7874666

ABSTRACT

Kraepelin proposed that schizophrenia and manic-depression were distinct and separable disorders. This hypothesis has been challenged recently by proponents of the "unitary psychosis" theory which posits a continuum from unipolar to bipolar disorder, continuing through schizoaffective and schizophrenic illness. In reviewing symptom cluster data and family studies, the author suggests that there is no compelling evidence to indicate a common pathophysiology for schizophrenia and bipolar disorder. More problematic is a diagnosis of schizoaffective disorder which does not appear to be a stable clinical entity. This would suggest that schizoaffective disorder is not a true clinical syndrome but rather a phenotypic variation.


Subject(s)
Bipolar Disorder/diagnosis , Schizophrenia/diagnosis , Schizophrenic Psychology , Bipolar Disorder/genetics , Bipolar Disorder/physiopathology , Bipolar Disorder/psychology , Brain/physiopathology , Diagnosis, Differential , Humans , Phenotype , Psychiatric Status Rating Scales , Psychotic Disorders/diagnosis , Psychotic Disorders/genetics , Psychotic Disorders/physiopathology , Psychotic Disorders/psychology , Schizophrenia/genetics , Schizophrenia/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...